Prostaglandin J2 family and the cardiovascular system

Current Vascular Pharmacology

Volumn 2, Issue 2, 2004, Pages 103-114

  Sasaguri, Toshiyuki ^a   Miwa, Yoshikazu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANGIOTENSIN 1 RECEPTOR; CELECOXIB; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 2; DELTA12 PROSTAGLANDIN J2; DNA; ENDOTHELIN 1; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIGAND; LIPOCALIN; LOW DENSITY LIPOPROTEIN RECEPTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN D2; PROSTAGLANDIN H2; PROSTAGLANDIN J2; PROSTAGLANDIN SYNTHASE; PROTEIN P21; ROFECOXIB; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; 9-DEOXY-DELTA-9-PROSTAGLANDIN D2; DRUG DERIVATIVE;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL DIFFERENTIATION; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CULTURE MEDIUM; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DNA SYNTHESIS INHIBITION; ENDOTHELIUM CELL; GROWTH INHIBITION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; HYPOTHESIS; IN VIVO STUDY; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; MITOSIS INHIBITION; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SYNTHESIS; REVIEW; SHEAR STRESS; SMOOTH MUSCLE FIBER; URINE LEVEL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR SYSTEM; CYTOLOGY; DRUG EFFECT; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INFLAMMATION; PROSTAGLANDIN D2;

EID: 3042704263     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043476384     Document Type: Review

References (142)

1. Fukushima M, Kato T, Narumiya S, Mizushima Y, Sasaki H, Terashima Y, et al. Prostaglandin A and J: antitumor and antiviral prostaglandins. Adv Prostaglandin Thromboxane Leukot Res 1989; 19: 415-8.
2. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-226.
3. 2: identification of products formed in vitro. J Biol Chem 1983; 258: 11713-8.
4. 2 formed in human plasma. Proc Natl Acad Sci USA 1984; 81: 1317-21.
5. Watanabe K, Urade Y, Mäder M, Murphy C, Hayaishi O. Identification of β-trace as prostaglandin D synthase. Biochem Biophys Res Commun 1994; 203: 1110-6.
6. 2 and sleep regulation. Biochim Biophys Acta 1999; 1436: 606-15.
7. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482: 259-71.
8. Urade Y, Hayaishi O. Prostaglandin D synthase: structure and function. Vitam Horm 2000; 58: 89-120.
9. Flower DR, North ACT, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000; 1482: 9-24.
10. Kanaoka Y, Ago H, Inagaki E, Nanayama T, Miyano M, Kikuno R, et al. Cloning and crystal structure of hematopoietic prostaglandin D synthase. Cell 1997; 90: 1085-95.
11. Eguchi Y, Eguchi N, Oda H, Seiki K, Kijima Y, Matsu-ura Y, et al. Expression of lipocalin-type prostaglandin D synthase (β-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 1997; 94: 14689-94.
12. 2 synthase expression in vascular endothelial cells. Circ Res 2000; 86: 967-73.
13. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803-12.
14. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83: 813-9.
15. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
16. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
17. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
18. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93: 229-40.
19. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
20. 1 arrest and differentiation in vascular smooth muscle cells. Mol Pharmacol 2000; 58: 837-44.
21. Marx N, Schönbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097-103.
22. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-104.
23. Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med 1999; 340: 115-26.
24. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21: 185-210.
25. 2 metabolite generated during inflammatory processes. J Biol Chem 2002; 277: 10459-66.
26. 2 in human urine. J Biol Chem 1988; 263: 16619-25.
27. Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat 2002; 68-69: 375-82.
28. Nagata A, Suzuki Y, Igarashi M, Eguchi N, Toh H, Urade Y, et al. Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins. Proc Natl Acad Sci USA 1991; 88: 4020-4.
29. Fujimori K, Kanaoka Y, Sakaguchi Y, Urade Y. Transcriptional activation of the human hematopoietic prostaglandin D synthase gene in megakaryoblastic cells: roles of the Oct-1 element in the 5′ -flanking region and the AP-2 element in the untranslated exon 1. J Biol Chem 2000; 275: 40511-6.
30. Mizoguchi A, Eguchi N, Kimura K, Kiyohara Y, Qu WM, Huang ZL, et al. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 2001; 98: 11674-9.
31. Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 1999; 96: 726-30.
32. 2 synthase mRNA is dependent on thyroid hormone during rat brain development. Biochem Biophys Res Commun 1993; 196: 396-401.
33. White DM, Takeda T, DeGroot LJ, Stefansson K, Arnason BGW. β-Trace gene expression is regulated by a core promoter and a distal thyroid hormone response element. J Biol Chem 1997; 272: 14387-93.
34. García-Fernández LF, Urade Y, Hayaishi O, Bernal J, Muñoz A. Identification of a thyroid hormone response element in the promoter region of the rat lipocalin-type prostaglandin D synthase (β-trace) gene. Mol Brain Res 1998; 55: 321-30.
35. García-Fernández LF, Iñiguez MA, Eguchi N, Fresno M, Urade Y, Muñoz A. Dexamethasone induces lipocalin-type prostaglandin D synthase gene expression in mouse neuronal cells. J Neurochem 2000; 75: 460-70.
36. Nollert MU, Eskin SG, McIntire LV. Shear stress increases inositol trisphosphate levels in human endothelial cells. Biochem Biophys Res Commun 1990; 170: 281-7.
37. Bhagyalakshmi A, Berthiaume F, Reich KM, Frangos JA. Fluid shear stress stimulates membrane phospholipid metabolism in cultured human endothelial cells. J Vasc Res 1992; 29: 443-9.
38. 2) and MAP kinase in human endothelial cells. Biochem Biophys Res Commun 1996; 218: 500-4.
39. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 10417-22.
40. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T. Transcriptional and post-transcriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1415-20.
41. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227: 1477-9.
42. Schönbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91.
43. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPARγ. J Biol Chem 2000; 275: 28028-32.
44. Ikeda Y, Sugawara A, Taniyama Y, Uruno A, Igarashi K, Arima S, et al. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2. J Biol Chem 2000; 275: 33142-50.
45. 2 derivative with potent antineoplastic and weak smooth muscle-contracting activities. Biochem Biophys Res Commun 1982; 109: 626-33.
46. 2: anti-tumour and anti-viral activities and the mechanisms involved. Eicosanoids 1990; 3: 189-99.
47. Santoro MG. Antiviral activity of cyclopentenone prostanoids. Trends Microbiol 1997; 5: 276-81.
48. 2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999; 59: 2739-46.
49. Sasaguri T, Masuda J, Shimokado K, Yokota T, Kosaka C, Fujishima M, et al. Prostaglandins A and J arrest the cell cycle of cultured vascular smooth muscle cells without suppression of c-myc expression. Exp Cell Res 1992; 200: 351-7.
50. Gartel AL, Serfas MS, Tyner AL. p21: negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213: 138-49.
51. Sdi1/Cip1/Waf1 by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 1997; 272: 10050-7.
52. Waf1/Cip1/Sdi1 in vascular smooth muscle cells. Mol Pharmacol 1999; 56: 938-46.
53. Sdi1/Cip1/Waf1. Circ Res 2000; 86: 185-90.
54. Bui T, Straus DS. Effects of cyclopentenone prostaglandins and related compounds on insulin-like growth factor-1 and Waf1 gene expression. Biochim Biophys Acta 1998; 1397: 31-42.
55. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1 --> S transition in vascular smooth muscle cells. J Biol Chem 2000; 275: 22435-41.
56. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273: 29864-72.
57. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-511.
58. Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, et al. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells. J Biol Chem 2003; 278: 9663-70.
59. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311-8.
60. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-905.
61. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, et al. Inhibition of cellular proliferation through 1κB kinase-independent and peroxisome proliferator-activated receptor γ -dependent repression of cyclin D1. Mol Cell Biol 2001; 21: 3057-70.
62. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995; 75: 487-517.
63. Tarrade A, Schoonjans K, Pavan L, Auwerx J, Rochette-Egly C, Evain-Brion D, et al. PPARγ/RXRα heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001; 86: 5017-24.
64. Komar CM, Braissant O, Wahli W, Curry TE Jr. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 2001; 142: 4831-8.
65. 2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells. Biochem Biophys Res Commun 1999; 258: 50-3.
66. 2 facilitates thyroglobulin production by cultured human thyrocytes. Am J Physiol Cell Physiol 2000; 279: C1859-69.
67. 2, a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun 1999; 262: 579-85.
68. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis. J Neurosci Res 2000; 61: 67-74.
69. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-5.
70. 2-induced apoptosis in breast cancer cells. J Biol Chem 2001; 276: 47131-5.
71. Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 2001; 287: 522-9.
72. 2: the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci USA 2002; 99: 7367-72.
73. Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, et al. Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ. Br J Cancer 2002; 86: 1303-9.
74. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-64.
75. Kojima K, Shimada T, Mitobe Y, Yoshiura K, Hiraishi H, Terano A. Effect of PPARγ ligands on the viability of gastric epithelial cells. Aliment Pharmacol Ther 2002; 16: 67-73.
76. Hamel L, Kenney M, Clark K, Merkel L, Rojas C. Preconditioning of human smooth muscle cells via cyclopentenone prostaglandins protects against toxic effects of oxidized low-density lipoprotein. Biochem Biophys Res Commun 2000; 269: 327-30.
77. 2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2003; 285: H38-H46.
78. Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, et al. Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor κB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001; 276: 31059-66.
79. 2, and peroxisome proliferator activated receptor-γ agonists induce apoptosis in transformed, but not normal, human T lineage cells. Immunology 2002; 105: 23-34.
80. 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol 2000; 165: 6941-8.
81. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-80.
82. Hortelano S, Castrillo A, Alvarez AM, Boscá L. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol 2000; 165: 6525-31.
83. 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of 1κBα degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism. J Immunol 2002; 168: 6232-43.
84. Kondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 2001; 276: 12076-83.
85. 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts: a pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 2001; 276: 38152-8.
86. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 2002; 277: 29681-5.
87. 2, ciglitazone, and GW1929. Exp Cell Res 2002; 277: 192-200.
88. 2 acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res 2000; 867: 115-21.
89. 2 is mediated by the stress response elements and transcriptional factor Nrf2. Antioxid Redox Signal 2002; 4: 249-57.
90. 2 integrin-dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation. J Immunol 1999; 163: 6187-92.
91. 2-induced expression of glutathione S-transferases. J Biol Chem 2000; 275: 11291-9.
92. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T, et al. PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 2001; 19: 465-71.
93. 2-mediated apoptosis of human colorectal carcinoma cells. Mol Cell Biol 1996; 16: 6654-60.
94. Liu Z, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996; 87: 565-76.
95. Madrid LV, Wang CY, Guttridge DC, Schottelius AJG, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol Cell Biol 2000; 20: 1626-38.
96. 2. J Biol Chem 1999; 274: 17042-8.
97. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999; 83: 555-63.
98. 2 on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1846-51.
99. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
100. WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-9.
101. Dimmeler S, Haendeler J, Rippmann V, Nehls M, Zeiher AM. Shear stress inhibits apoptosis of human endothelial cells. FEBS Lett 1996; 399: 71-4.
102. Kaiser D, Freyberg MA, Friedl P. Lack of hemodynamic forces triggers apoptosis in vascular endothelial cells. Biochem Biophys Res Commun 1997; 231: 586-90.
103. Jin X, Mitsumata M, Yamane T, Yoshida Y. Induction of human inhibitor of apoptosis protein-2 by shear stress in endothelial cells. FEBS Lett 2002; 529: 286-92.
104. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106: 189-97.
105. 2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168: 2508-15.
106. 2 attenuates the development of acute and chronic inflammation. Mol Pharmacol 2002; 61: 997-1007.
107. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999; 104: 383-9.
108. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med 1999; 5: 698-701.
109. Zhu L, Bisgaier CL, Aviram M, Newton RS. 9-cis Retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler Thromb Vasc Biol 1999; 19: 2105-11.
110. 2 and polyunsaturated fatty acids. Biochem Pharmacol 2002; 63: 1183-9.
111. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999; 274: 8328-34.
112. Callejas NA, Castrillo A, Boscá L, Martín-Sanz P. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J Pharmacol Exp Ther 1999; 288: 1235-41.
113. 2 in activated human astrocytes, but not in human brain macrophages. J Immunol 2002; 168: 4747-55.
114. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844-9.
115. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000; 403: 103-8.
116. 2 in activated murine macrophages. Mol Cell Biol 2000; 20: 1692-8.
117. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 2001; 276: 35530-6.
118. 1: an effect associated with heat shock transcription factor activation. Proc Natl Acad Sci USA 1997; 94: 746-50.
119. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, et al. PPAR γ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999; 33: 798-806.
120. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-21.
121. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
122. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, et al. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-9.
123. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-5.
124. Chiba Y, Ogita T, Ando K, Fujita T. PPARγ ligands inhibit TNF-α-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun 2001; 286: 541-6.
125. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546-51.
126. 2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens 2002; 20: 1347-54.
127. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
128. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci USA 1994; 91: 11192-6.
129. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270: 18910-6.
130. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-61.
131. 2 as a mediator of allergic asthma. Science 2000; 287: 2013-7.
132. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002; 168: 443-9.
133. 2. Biochem J 1985; 232: 267-71.
134. 2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res 1992; 71: 1305-13.
135. Inoue T, Takayanagi K, Morooka S, Uehara Y, Oda H, Seiki K, et al. Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis. Thromb Haemost 2001; 85: 165-70.
136. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998; 18: 677-85.
137. Hirawa N, Uehara Y, Yamakado M, Toya Y, Gomi T, Ikeda T, et al. Lipocalin-type prostaglandin D synthase in essential hypertension. Hypertension 2002; 39: 449-54.
138. Hirawa N, Uehara Y, Ikeda T, Gomi T, Hamano K, Totsuka Y, et al. Urinary prostaglandin D synthase (β-trace) excresion increases in the early stage of diabetes mellitus. Nephron 2001; 87: 321-7.
139. Hamano K, Totsuka Y, Ajima M, Gomi T, Ikeda T, Hirawa N, et al. Blood sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients. Nephron 2002; 92: 77-85.
140. Oda H, Shiina Y, Seiki K, Sato N, Eguchi N, Urade Y. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin Chem 2002; 48: 1445-53.
141. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3.
142. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23.